Edition:
United Kingdom

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

8.44EUR
21 Sep 2018
Change (% chg)

€-0.22 (-2.54%)
Prev Close
€8.66
Open
€8.76
Day's High
€8.76
Day's Low
€8.43
Volume
52,180
Avg. Vol
44,006
52-wk High
€29.70
52-wk Low
€8.43

Latest Key Developments (Source: Significant Developments)

Erytech Pharma Q1 Net Loss Widens To 11.7 Million Euros
Monday, 14 May 2018 

May 14 (Reuters) - ERYTECH PHARMA SA ::CASH POSITION OF €171.8 MILLION ($211.6 MILLION) AS OF MARCH 31, 2018.FINALIZED PHASE 3 TRIAL DESIGN FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER; ON TRACK FOR EXPECTED START OF PATIENT ENROLLMENT IN Q3.SELECTED TRIPLE-NEGATIVE BREAST CANCER AS THE NEXT SOLID TUMOR INDICATION; PREPARING PHASE 2 TRIAL WITH EXPECTED START OF PATIENT ENROLLMENT IN Q3.REPORTED POSITIVE U.S. PHASE 1 TRIAL RESULTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA; DISCUSSION WITH FDA UPCOMING.Q1 NET LOSS EUR 11.7 MILLION VERSUS LOSS OF EUR 6.5 MILLION YEAR AGO.  Full Article

Erytech Appoints Alex Dusek As VP Of Commercial Strategy
Monday, 14 May 2018 

May 14 (Reuters) - ERYTECH PHARMA SA ::ERYTECH STRENGTHENS EXECUTIVE TEAM WITH THE APPOINTMENT OF ALEX DUSEK AS VP OF COMMERCIAL STRATEGY.  Full Article

Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML
Friday, 8 Dec 2017 

Dec 8 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS TOP-LINE RESULTS OF PHASE 2B STUDY OF ERYASPASE FOR THE TREATMENT OF AML.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS).OS HAZARD RATIO (HR) WAS 1.06 (95% CI; 0.70, 1.61).WHEN ADJUSTING FOR MINOR IMBALANCES IN MAIN PROGNOSTIC FACTORS AT BASELINE OS HR WAS 0.98 (95% CI; 0.64, 1.50).MEDIAN NUMBER OF MONTHS ON TREATMENT WAS LESS THEN 2 MONTHS IN BOTH TREATMENT ARMS.  Full Article

Erytech Pharma SA ADS debut about 14.7 pct above IPO price
Friday, 10 Nov 2017 

Nov 10 (Reuters) - :Erytech Pharma SA ADS open at $26.68 in debut on the NASDAQ versus IPO price of $23.26 per ADS‍​‍​​.  Full Article

Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​.‍GLOBAL OFFERING COMPRISING AN OFFER OF 4.7 MILLION ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES​.IN ‍UNITED STATES, OFFERING PRICE OF $23.26 PER ADS​.‍PRIVATE PLACEMENT IN EUROPE (INCL. FRANCE) AND OTHER COUNTRIES (EXCLUDING. US AND CANADA) OF 0.7 MILLION ORDINARY SHARES AT OFFERING PRICE OF EUR 20 PER SHARE.‍LISTING ON NASDAQ GLOBAL SELECT MARKET UNDER TICKER SYMBOL "ERYP"​.‍GLOBAL OFFERING FOR TOTAL GROSS PROCEEDS OF ABOUT $125 MILLION BEFORE DEDUCTING UNDERWRITING COMMISSIONS AND ESTIMATED EXPENSES PAYABLE BY CO​.‍CLOSING OF GLOBAL OFFERING EXPECTED ON OR ABOUT NOV 14, 2017​.‍FOLLOWING CLOSING COMPANY WILL HAVE ISSUED 5,374,033 ORDINARY SHARES (INCL. ADSS)​.  Full Article

Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS.SUSPENSION TO ALLOW FOR CONFIRMATION OF ALLOCATIONS TO INVESTORS & CO'S ADSS BEGINNING TRADING ON NASDAQ GLOBAL SELECT MARKET .‍SUSPENSION EFFECTIVE UNTIL A NEW COMMUNICATION IS RELEASED BY COMPANY​.‍TRADING ON REGULATED MARKET OF EURONEXT PARIS EXPECTED TO RESUME NOV 10, 2017 ABOUT 4:00 PM (CET)​.  Full Article

Erytech Pharma 9M net loss widens to 20.8 million euros
Tuesday, 7 Nov 2017 

7 Nov(Reuters) - ERYTECH PHARMA SA ::ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 80.3 MLN ON SEPT 30, VS 88.5 MLN ON JUNE 30.FINANCIAL RESULTS ARE IN LINE WITH STRATEGY FOR 2017.  Full Article

Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Erytech Pharma SA :Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing.Erytech Pharma SA says U.S. IPO price is expected to be between $23.00 and $24.00 per ADS.  Full Article

BRIEF-Erytech To Present Results From Phase I Trial Of Eryaspase In All And New Pre Clinical Data At Aacr 2018

* ERYTECH TO PRESENT RESULTS FROM PHASE I TRIAL OF ERYASPASE IN ALL AND NEW PRE-CLINICAL DATA AT AACR 2018 Source text for Eikon: Further company coverage: